Scancell Hldgs Plc (SCLP) - Total Liabilities

Latest as of October 2025: GBX23.75 Million GBX ≈ $2.89K USD

Based on the latest financial reports, Scancell Hldgs Plc (SCLP) has total liabilities worth GBX23.75 Million GBX (≈ $2.89K USD) as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Scancell Hldgs Plc - Total Liabilities Trend (2005–2025)

This chart illustrates how Scancell Hldgs Plc's total liabilities have evolved over time, based on quarterly financial data. See Scancell Hldgs Plc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Scancell Hldgs Plc Competitors by Total Liabilities

The table below lists competitors of Scancell Hldgs Plc ranked by their total liabilities.

Company Country Total Liabilities
Prominence Energy Ltd
AU:PRM
Australia AU$127.04K
Inspecs Group plc
LSE:SPEC
UK GBX114.73 Million
Fjordland Exploration Inc
V:FEX
Canada CA$125.33K
Pacific Imperial Mines Inc
V:PPM
Canada CA$465.84K
Motorpoint Group PLC
LSE:MOTR
UK GBX255.90 Million
KOOL2PLAY S.A. ZY -10
F:8Q8
Germany €3.89 Million
XTL Biopharmaceuticals Ltd
F:H2K2
Germany €3.12 Million

Liability Composition Analysis (2005–2025)

This chart breaks down Scancell Hldgs Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Scancell Hldgs Plc (SCLP) total assets.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.56 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -2.84 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.54 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Scancell Hldgs Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Scancell Hldgs Plc (2005–2025)

The table below shows the annual total liabilities of Scancell Hldgs Plc from 2005 to 2025.

Year Total Liabilities Change
2025-04-30 GBX26.93 Million
≈ $3.28K
-0.58%
2024-04-30 GBX27.08 Million
≈ $3.29K
-25.81%
2023-04-30 GBX36.50 Million
≈ $4.44K
+23.43%
2022-04-30 GBX29.57 Million
≈ $3.60K
+2427.61%
2021-04-30 GBX1.17 Million
≈ $142.36
-2.94%
2020-04-30 GBX1.21 Million
≈ $146.66
0.00%
2019-04-30 GBX1.21 Million
≈ $146.66
+73.17%
2018-04-30 GBX696.09K
≈ $84.69
+30.87%
2017-04-30 GBX531.88K
≈ $64.71
-7.60%
2016-04-30 GBX575.65K
≈ $70.04
-4.68%
2015-04-30 GBX603.91K
≈ $73.48
+12.34%
2014-04-30 GBX537.59K
≈ $65.41
+70.60%
2013-04-30 GBX315.11K
≈ $38.34
+10.81%
2012-04-30 GBX284.38K
≈ $34.60
+133.10%
2011-04-30 GBX122.00K
≈ $14.84
-73.01%
2010-04-30 GBX452.00K
≈ $55.00
+170.66%
2009-04-30 GBX167.00K
≈ $20.32
+89.02%
2008-04-30 GBX88.35K
≈ $10.75
-57.15%
2007-04-30 GBX206.21K
≈ $25.09
+415.52%
2006-04-30 GBX40.00K
≈ $4.87
-31.03%
2005-08-31 GBX58.00K
≈ $7.06
--

About Scancell Hldgs Plc

LSE:SCLP UK Biotechnology
Market Cap
$1.20 Million
GBX9.86 Billion GBX
Market Cap Rank
#30456 Global
#775 in UK
Share Price
GBX9.50
Change (1 day)
+0.53%
52-Week Range
GBX8.54 - GBX26.50
All Time High
GBX27.50
About

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more